Jan 27, 2023 · 1h 38m · allin
E113: DOJ tries to break up Google, vaccine questions, Ukraine escalation & more
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In Episode 113 of the All-In Podcast, hosts Jason Calacanis, Chamath Palihapitiya, David Sacks, and David Friedberg analyze the DOJ antitrust lawsuit against Google, Microsoft's enterprise bundling practices, COVID-19 vaccine safety data and mandates, escalating military support for Ukraine, and groundbreaking longevity research.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. The hosts hold 98.9% of the talking time here. How this is scored →
speaking balance: gold is the hosts, purple is the guest (3 minute bins)
The reporter relentlessly follows Pfizer CEO Albert Bourla through the streets of Davos, repeatedly rejecting his evasions and demanding to know why Pfizer kept vaccine transmission limits secret.
Hardest push from the hosts ▶ 1:03:50 Sacks confronts Calacanis with his Jan 2022 vaccine tweetSacks directly refuses Calacanis's reframe that he never supported vaccine coercion, reading Calacanis's own tweet aloud to expose inconsistency and force a direct defense.
Biggest teaching moment ▶ 1:26:20 Friedberg educates panel on epigenetics and Yamanaka factorsFriedberg provides an authoritative biology masterclass on the information theory of aging, teaching the co-hosts how epigenetic degradation rather than DNA mutation drives cellular aging.
The host holds their own ▶ 4:03 Chamath dismantles DOJ monopoly framing with ad market share dataChamath demonstrates expert domain knowledge by citing granular digital ad market statistics to prove Google lacks classic monopoly concentration compared to 1980s Ma Bell.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The hosts as informed peer | Guest teaching | Guest disagreement | The hosts pushing back | Why |
|---|---|---|---|---|---|---|
| DOJ Lawsuit to Break Up Google's Ad Tech Business | 8 | 4 | 3 | 4 | Chamath details digital ad market shares (Google 26.5%, Meta 18.4%, Amazon 11.7%, Others 43.4%), contrasting Google's position with Ma Bell's 1980s 100% monopoly to argue the DOJ lawsuit is ill-founded. Sacks moderates by raising the antitrust filing, while Chamath provides detailed market analysis. | |
| Friedberg's Analysis of Google's Auction Model & Publisher Payouts | 9 | 7 | 2 | 5 | Friedberg draws on his AdSense and AdWords experience since 2002 to explain how Google's auction model and 70-80% publisher revenue share prevent monopoly rents. Sacks uses a DOJ diagram to probe sell-side vs buy-side market concentration. | |
| Government Unwinding Decade-Old Deals & Impact on M&A | 6 | 3 | 2 | 4 | Calacanis, Sacks, and Chamath critique the DOJ trying to unwind DoubleClick fifteen years post-acquisition, noting it creates market uncertainty and chills tech M&A. | |
| Shifting Ad Market Dynamics: Amazon, Third-Party Cookies & Apple IDFA | 8 | 6 | 1 | 3 | Friedberg outlines how Amazon's e-commerce ad growth, Apple's IDFA deprecation, and 2024 third-party cookie removal are naturally decentralizing ad spend. Chamath highlights these shifts as evidence of dynamic market self-regulation. | |
| Monopolistic Targets: App Store Duopolies vs. Regulatory Misdirection | 7 | 4 | 6 | 6 | Chamath forcefully pushes back when Calacanis draws an analogy to Xi Jinping and Jack Ma, calling out Calacanis for virtue signaling about China. Sacks and Chamath argue regulators should focus on true duopolies like Apple and Google's app stores. | |
| EU Antitrust Probe into Microsoft Teams & Slack's Complaint | 8 | 6 | 2 | 4 | Chamath shares insider perspective from his time on Slack's board during its IPO, explaining how Microsoft Teams used distribution bundling to counter Slack's superior product. Sacks introduces the EU antitrust probe into Microsoft bundling. | |
| Predatory Bundling, ELAs & Sacks' Unbundling Proposal | 7 | 4 | 4 | 6 | Sacks argues Microsoft's enterprise bundling degrades startup moats in B2B software, while Chamath suggests regulatory transparency for Enterprise Licensing Agreements (ELAs). Calacanis questions whether consumers suffer actual harm. | |
| The Software Dumping Debate: Free Market vs. Antitrust Protections | 7 | 6 | 7 | 7 | Friedberg strongly rejects Sacks' framing that bundling constitutes software dumping, arguing that superior differentiated software will win regardless of discounts. Sacks counters that software reverse engineering makes bundling inherently predatory. | |
| SaaS Innovation Moats & The Comcast / Netflix Analogy | 8 | 5 | 7 | 7 | Chamath challenges Friedberg using a Comcast and Netflix analogy to show how distribution rails can smother application innovation. Sacks compares software bundling to Chinese steel dumping to justify regulatory oversight. | |
| Practical Regulatory Remedies for B2B Software Markets | 8 | 5 | 2 | 4 | Chamath outlines regulatory remedies including transfer-pricing transparency and sum-of-the-parts pricing rules, drawing parallels to Pfizer's healthcare R&D accounting mandates. | |
| Pfizer CEO Albert Bourla Confronted at Davos by Rebel News | 6 | 4 | 8 | 6 | Sacks plays a video clip of a Rebel News reporter aggressively questioning Pfizer CEO Albert Bourla at Davos regarding vaccine transmission claims. Friedberg warns about platform downranking while Sacks defends press questioning. | |
| Medical Studies on Vaccine Safety & Myocarditis Risks | 9 | 8 | 2 | 5 | Friedberg breaks down a Mass General study published in Circulation demonstrating that uncleared spike protein in blood correlates with myocarditis cases in young men. Sacks probes the timeline and safety risks compared to French Nature studies. | |
| Vaccine Mandates, Media Pressure, and Efficacy Questions | 6 | 4 | 3 | 6 | Sacks questions whether Joe Rogan was prematurely vilified for opposing young adult vaccination, while Calacanis reflects on travel mandates driving personal choices. Sacks stresses the intense social and legal coercion present in 2021. | |
| FDA Approval Pathways, Emergency Use Authorization, and Myocarditis Research | 9 | 8 | 2 | 4 | Chamath outlines FDA approval pathways, contrasting 12-year standard drug timelines with Emergency Use Authorization (EUA) shortcuts for mRNA vaccines, citing his own co-authored cardiology paper on troponin spikes. | |
| Institutional Trust, Mandate Controversies, and Personal Regrets | 7 | 5 | 5 | 7 | Friedberg highlights post-activity rationalization by public health officials that broke institutional trust. Sacks presses Calacanis on whether elites suffered from groupthink regarding lockdowns and mandates. | |
| Debating Past Vaccine Tweets, Booster Efficacy, and Pharma Incentives | 7 | 5 | 7 | 8 | Sacks confronts Calacanis by reading a January 2022 tweet where Calacanis accused Fox News and Trump of killing constituents with anti-vax sentiment. Calacanis vigorously defends his post before all four hosts agree they will decline future boosters. | |
| Escalation in Ukraine, Tank Deliveries, and Reconstruction Costs | 8 | 6 | 4 | 6 | Sacks outlines Ukraine escalation, citing Abrams tank deliveries and Larry Fink's $750B reconstruction estimate. Friedberg details Russian tactical nuclear doctrine risks while Chamath and Calacanis call for an exit ramp. | |
| Science Corner: Epigenetics, Yamanaka Factors, and Reversing Aging | 10 | 9 | 2 | 4 | Friedberg presents a Harvard study on the epigenome and information theory of aging, explaining how DNA breaks degrade cellular software and how Yamanaka factors reset gene expression. Sacks and Chamath ask about practical clinical horizons. |